CompareRx Newsroom
GLP-1 news and today's most-asked questions
We monitor FDA actions, manufacturer announcements, pricing moves and search trends around the clock, then publish what actually changes the math for people buying GLP-1 care online.
Coverage areas: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), retatrutide and next-generation obesity drugs, FDA approvals and regulatory action, clinical trial results, GLP-1 pricing, insurance coverage, telehealth developments, compounding regulation, and pharmaceutical company announcements. Written by the CompareRx editorial team under our editorial policy.
WHO issues pediatric obesity guidelines — adding clinical hurdles for US GLP-1 buyers
The WHO's first pediatric obesity guidelines recommend lifestyle programs over GLP-1s for adolescents, shaking up US telehealth and insurance standards.
Semaglutide shows promise in reversing heart failure — what clinical data changes for telehealth buyers
A new study in the European Heart Journal shows semaglutide may reverse obesity-related heart failure, offering key clinical data for cash GLP-1 buyers.
Obese dementia patients live longer — what the 'obesity paradox' changes for senior GLP-1 buyers
A new Journal of Alzheimer's Disease study reveals patients with obesity live longer after a dementia diagnosis, shaking up senior GLP-1 decisions.
Teen GLP-1 prescriptions surge 20-fold — what the undertreatment data means for telehealth buyers
A JAMA Pediatrics study shows teen GLP-1 prescriptions surged from 2017 to 2025, but 90% of eligible adolescents still face an obesity care gap.
Lilly’s retatrutide drives 18.8% weight loss in diabetes trial — setting a new benchmark for cash-pay GLP-1 buyers
Lilly’s Phase III TRIUMPH-2 trial reveals retatrutide drives an historic 18.8% weight loss in type 2 diabetes—setting a new benchmark for GLP-1 buyers.
Novo CagriSema beats tirzepatide in REIMAGINE 5 trial — bolstering next-gen GLP-1 competition
Novo Nordisk’s CagriSema beats tirzepatide in the head-to-head REIMAGINE 5 trial, paving the way for a highly potent next-generation weight-loss drug.
Boehringer obesity drug disappoints in trial — narrowing options for US GLP-1 buyers
Boehringer and Zealand Pharma's obesity drug posts a disappointing 13.1% weight loss in trials, narrowing pipeline options for US cash-pay GLP-1 buyers.
FDA warns Empower Pharmacy over mass GLP-1 copies — closing the telehealth loophole
The FDA has issued a warning letter to Empower Pharmacy over mass-produced compounded GLP-1s and insanitary conditions. What this means for telehealth buyers.
Lilly combo drives 23.3% weight loss in diabetes — but 27% dropout rate poses cash-market hurdle
Eli Lilly’s eloralintide-tirzepatide combo drives 23.3% weight loss in diabetics, but a 27% dropout rate highlights safety hurdles for cash telehealth buyers.
Boehringer’s survodutide yields modest 9.8% weight loss — why Phase III dropout rates matter for GLP-1 buyers
Boehringer’s Phase III SYNCHRONIZE-2 trial reveals modest 9.8% weight loss and a 26% dropout rate, highlighting tolerability hurdles for US GLP-1 buyers.
Postpartum GLP-1 prescriptions jump 20-fold — what the surge means for online weight-loss buyers
Postpartum GLP-1 prescriptions jumped 20-fold from 2018 to 2025. Here is what the JAMA study means for US weight-loss buyers and telehealth safety.
Study links GLP-1 use to fourfold risk of detached fingernails — the new safety data for telehealth buyers
A prospective EADV study links GLP-1 medications to a fourfold higher risk of detached fingernails (onycholysis). What this means for telehealth buyers.
Feds charge international ring over fake Ozempic — what the crackdown changes for US cash buyers
Federal charges against international smugglers distributing fake Ozempic highlight safety risks, driving US buyers to verified telehealth providers.
Pediatric obesity linked to ninefold kidney disease risk — why early GLP-1 care matters
A new study reveals children with severe obesity face a ninefold risk of kidney disease and 40-fold liver mortality, framing early GLP-1 care as vital.
Wegovy reverses obesity in 40% of kids — what pediatric data changes for cash buyers
A new analysis reveals Wegovy reverses obesity in 40% of pediatric patients. Learn what this clinical trial data means for US parents shopping telehealth.
Lilly’s daily weight-loss pill orforglipron passes key heart safety trial — what it changes for telehealth buyers
Eli Lilly’s daily oral weight-loss pill orforglipron passes a key cardiovascular safety milestone in the Phase III ACHIEVE-4 trial. What this means for buyers.
Two studies find no fetal risk from early GLP-1 exposure — what the clinical reassurance means for telehealth buyers
Two new meta-analyses of over 2.1 million pregnancies find no clear link between early GLP-1 exposure and birth defects, offering clinical reassurance.
Lilly’s Zepbound-amylin combo drives 23.3% weight loss — but high dropout rates signal tolerability risks for cash buyers
Eli Lilly’s Zepbound-amylin combo drove a massive 23.3% weight loss in a Phase II trial, but high dropout rates highlight severe tolerability challenges.
Study links functional decline to decade before heart events — why early GLP-1 telehealth intervention matters
A new JAMA Cardiology study reveals functional decline starts 10 years before heart events. Learn why early GLP-1 telehealth intervention is crucial.
Teens on GLP-1s face 17% nutritional deficiency rate — the hidden risk of budget telehealth plans
A new study reveals nearly 17% of teens on GLP-1s develop nutritional deficiencies. Learn what this means for US buyers shopping online.
Roche halts early-stage obesity drug emugrobart — narrowing options for US GLP-1 buyers
Roche halts development on its early-stage obesity drug emugrobart, narrowing pipeline options for US GLP-1 buyers as Novo and Lilly maintain their duopoly.
Novo shifts GLP-1 marketing to lifestyle branding — what it changes for telehealth buyers
Novo Nordisk shifts its GLP-1 positioning from chronic disease treatment to consumer lifestyle products, reshaping how US telehealth platforms package care.
CVS survey reveals employers overhaul GLP-1 benefits — driving buyers to cash telehealth
Surging GLP-1 costs are forcing U.S. employers to cut coverage. Learn how CVS Health survey findings are driving patients to cash-pay telehealth.
GLP-1 marketing shifts to lifestyle branding — what it changes for telehealth buyers
GLP-1 marketing is shifting from obesity treatment to lifestyle branding. Learn what this direct-to-consumer commercialization means for telehealth buyers.
Novo evaluates NYSE direct listing — what the corporate move changes for US GLP-1 buyers
Novo CEO Mike Doustdar reveals openness to a direct NYSE listing. Read what this financial move means for US Wegovy shortages and GLP-1 buyers.
Roche oral obesity pill CT-996 matches injectable weight loss — challenging the cash-pay telehealth market
Roche's oral GLP-1 pill CT-996 matches injectable weight loss in Phase I trial. Read what this pipeline progress means for US cash-pay telehealth buyers.
Fierce Pharma launches oral GLP-1 tracker — what it changes for telehealth buyers
Fierce Pharma launches a weekly Oral GLP-1 Tracker for the Wegovy pill and Lilly’s Foundayo. Discover what this means for online telehealth buyers.
FDA warns Empower Pharmacy over mass-produced GLP-1s — closing the telehealth compounding loophole
The FDA warns Empower Pharmacy over mass production of compounded GLP-1 copycats and insanitary conditions. Read what this means for telehealth buyers.
Lilly claims 70% share of Medicare GLP-1 program — what it means for cash buyers
Eli Lilly CEO David Ricks reveals the company controls 70% of the Medicare GLP-1 pilot. Learn what this supply shift means for cash-paying GLP-1 buyers.
Stopping GLP-1s raises heart attack risk by 22% — the cost of therapy gaps for cash buyers
Stopping GLP-1 drugs for two years raises the risk of heart attack, stroke, and death by 22%, making continuous therapy crucial for US buyers.
Oral Wegovy linked to superior weight loss for recent gain — the clinical math for telehealth buyers
Real-world data shows oral Wegovy is highly effective for patients reversing recent weight gain. Read the clinical math for US telehealth buyers.
Oak launches $119 compounded GLP-1 plans — squeezing cash-pay telehealth weight-loss pricing
Oak launches a $119 compounded GLP-1 weight-loss plan with no membership fees, significantly lowering cash-pay costs for US online buyers.
Novo faces investor pressure to diversify beyond Wegovy — what it means for US GLP-1 buyers
Investors are pushing Wegovy-maker Novo to diversify beyond semaglutide as patent cliffs loom and Eli Lilly's Zepbound dominates the market.
Haleon targets GLP-1 side effects in CVS aisles — carving out a new cash-pay companion market
Advil maker Haleon is partnering with CVS to launch dedicated GLP-1 side-effect aisles, driving a 24% sales lift for over-the-counter companion remedies.
Novo CagriSema beats tirzepatide in REIMAGINE 5 trial — bolstering next-gen GLP-1 competition
Novo's next-gen CagriSema beats Eli Lilly's tirzepatide in the REIMAGINE 5 trial, paving the way for an FDA decision and an early next year launch.
CagriSema beats tirzepatide 5 mg in Phase III trial — redefining the next-gen GLP-1 market
Novo Nordisk’s CagriSema beat Eli Lilly’s tirzepatide 5 mg in a Phase III trial. Read what this clinical data means for next-gen online GLP-1 buyers.
Patients sue GLP-1 makers over rare NAION vision loss — what safety lawsuits mean for telehealth buyers
Dozens of patients are suing GLP-1 makers over rare NAION vision loss. Learn what these safety lawsuits mean for US online telehealth buyers.
Novo outlines direct-to-consumer strategy — what it changes for GLP-1 buyers
Novo outlines a direct-to-consumer pivot to launch five new blockbusters by 2030, shifting how US buyers access brand-name weight-loss drugs.
Novo’s Wegovy benefits frail heart patients — what clinical data changes for online GLP-1 buyers
A new SELECT trial analysis shows Novo's Wegovy reduces heart risks, reverses frailty, and boosts quality of life for high-risk cardiovascular patients.
Novo’s new CEO defends strategy — what it changes for brand-name buyers
Novo's new CEO Mike Doustdar defends corporate strategy amid the GLP-1 market battle with Eli Lilly. Read what this leadership shift changes for US buyers.
FDA clears Beta Bionics' Mint patch pump — simplifying wearable tech for US diabetes buyers
The FDA clears Beta Bionics' Mint patch pump, bringing a rechargeable-free, smartphone-controlled insulin delivery option to US diabetes buyers.
Obesity drugmakers target kids as young as six — what pediatric trials mean for GLP-1 buyers
Obesity drugmakers are launching pediatric trials for children as young as six. Here is what younger age groups mean for GLP-1 costs and telehealth.
Trump proposes $500 health cash checks — the GLP-1 telehealth math for cash buyers
A proposed $500 direct cash payment for ACA enrollees could act as a direct subsidy for patients paying cash for monthly GLP-1 telehealth programs.
GLP-1 muscle loss reaches up to 40% — what body composition data changes for online buyers
Clinical data shows 15% to 40% of GLP-1 weight loss comes from muscle. Learn what this body composition risk means for US online telehealth buyers.
Novo Nordisk rebrands to ‘Novo’ — what the corporate shift means for GLP-1 buyers
Novo Nordisk drops 'Nordisk' to rebrand as 'Novo' amid its intense GLP-1 market battle with Eli Lilly. Here is what the corporate shift means for US buyers.
House proposes 70% cut to CDC obesity division — cementing the US shift to private GLP-1 care
The U.S. House proposes a 70% budget cut to the CDC's obesity division, signaling a massive shift from federal prevention to private GLP-1 telehealth.
Quel launches GLP-1 programs for addiction — what behavioral telehealth changes for cash buyers
Telehealth startup Quel launches GLP-1 programs specifically for addiction. Learn how this behavioral shift changes online clinical care and pricing.
GLP-1s linked to 14% drop in asthma and COPD attacks — the pulmonary math for online buyers
A new observational study shows GLP-1 drugs, especially semaglutide, link to a 14% drop in asthma and COPD attacks. Learn what this means for US cash buyers.
FDA warns against multidose vials for compounded GLP-1s — the safety risk for online buyers
The FDA warns against multidose vials for compounded GLP-1s. Learn what this new safety alert means for online buyers using syringes and vials.
Novo's Wegovy reverses obesity in 40% of kids — what pediatric data changes for cash buyers
A Phase 3 trial shows Wegovy reverses pediatric obesity in 40% of children. Read what these clinical milestones mean for cash-paying US families.
UCSF researchers warn GLP-1s are no magic bullet — advocating for tobacco-style food regulations
UCSF researchers warn that medicalizing obesity with GLP-1s ignores the systemic food environment, advocating for tobacco-style food regulations.
GLP-1 prescribing leaps 310-fold in children under 12 — what the pediatric surge means for cash buyers
A new study reveals a 310-fold surge in off-label GLP-1 prescriptions for children under 12, highlighting a major clinical shift for families.
GLP-1 prescriptions surge 500% in serious mental illness — what the clinical shift changes for cash buyers
GLP-1 prescribing surged 500% from 2018 to 2024 for patients with serious mental illness, as clinical safety confidence drives cash-pay telehealth demand.
Medicare $50 GLP-1 pilot drives blockbuster sales — why it impacts telehealth cash buyers
Medicare's $50 GLP-1 bridge program is generating blockbuster sales volumes. Learn how this massive surge in senior demand affects cash-paying telehealth buyers.
FDA finds pesticide in weight-loss supplement — highlighting safety advantages of regulated GLP-1 care
The FDA recalled Lipofit Extreme Fat Burner 2.0 after discovering a toxic pesticide and an antidepressant, exposing risks of unregulated weight-loss pills.
GLP-1 use expands into dermatology — what rising off-label prescribing means for online buyers
Dermatologists are increasingly prescribing GLP-1s off-label for psoriasis, raising medicolegal risks and changing how US buyers navigate online care.
CVS and Walgreens fill 200,000 Medicare $50 GLP-1 prescriptions — the telehealth cash divide
CVS and Walgreens have filled 200,000 Medicare $50 GLP-1 prescriptions. Learn how this massive volume impacts cash-paying telehealth buyers.
GLP-1s cut tuberculosis and infection risks — expanding the therapy’s clinical value for cash buyers
New research shows GLP-1 drugs like tirzepatide reduce active TB risks up to 51% and cut infection-related mortality, highlighting powerful immune benefits.
Youth GLP-1 study links treatment to 62% higher gallbladder risk — what the safety data means for younger buyers
A new JAMA Pediatrics study links youth GLP-1 use to a 62% higher risk of biliary colic. Here is what the gallbladder safety data means for young buyers.
CVS Health survey reveals employers overhaul benefits as GLP-1 costs surge — driving buyers to telehealth cash options
A CVS Health survey reveals employers are overhauling benefits as GLP-1 costs surge. Learn what this coverage squeeze means for telehealth cash buyers.
Roche expands obesity pipeline with $2.5B Akeso deal — challenging Lilly and Novo's market grip
Roche secures global rights to Akeso's novel metabolic asset in a $2.5B deal, challenging Novo and Lilly with next-generation bispecific therapies.
Half of Wegovy patients quit within a year — what high dropout rates mean for cash-paying US buyers
A new Danish study reveals 49% of Wegovy users stop treatment within a year. Learn why patients discontinue and what it means for US telehealth buyers.
FDA approves Mounjaro for cardiovascular risk reduction — matching a key Novo Nordisk advantage
The FDA expanded Mounjaro's approval to include reducing heart attack and stroke risks, matching a key cardiovascular benefit previously held by Ozempic.
Dolly Parton dies at 80 — as 14% of employers plan to cut GLP-1 coverage
Dolly Parton dies at 80, leaving a massive healthcare philanthropy legacy. Plus, 14% of large employers plan to drop GLP-1 coverage next year.
Medicare excludes sickest seniors from $50 GLP-1 pilot — driving buyers to telehealth cash options
Medicare’s new $50 GLP-1 Bridge program is rejecting seniors with comorbidities like sleep apnea, pushing high-risk patients to search for telehealth cash options.
Gray market retatrutide fails to match clinical trial weight loss — exposing online peptide risks
A new preprint study shows gray market retatrutide fails to match clinical trial weight loss. Learn what this means for US online peptide buyers.
Eli Lilly targets Medicare coverage of obesity treatment — why the manufacturer’s push matters for GLP-1 buyers
Eli Lilly launches a major media campaign targeting Medicare and Medicaid coverage for weight-loss drugs. Learn how this affects US GLP-1 buyers.
Fierce Pharma launches oral GLP-1 tracker — what prescription trends mean for US buyers
Fierce Pharma launches a weekly Oral GLP-1 Tracker to monitor Novo's oral Wegovy and Lilly's Foundayo. Read what prescription trends mean for US buyers.
Study links GLP-1s to ulcerative colitis remission — expanding anti-inflammatory benefits for online buyers
A new study links semaglutide and liraglutide to rapid ulcerative colitis remission, revealing powerful gut anti-inflammatory benefits for GLP-1 buyers.
GLP-1s cut mental illness mortality by 24% — why cardiac protection matters for telehealth buyers
A massive new study shows newer GLP-1 drugs cut mortality by 24% in adults with mental illness, highlighting critical cardiovascular benefits for US buyers.
Eli Lilly’s orforglipron pill achieves 11% weight loss — paving way for needle-free alternatives
Eli Lilly’s oral weight-loss pill orforglipron achieves 11% weight loss in trials. Read what this needle-free, small-molecule GLP-1 means for US buyers.
Studies expose why some GLP-1 patients fail to lose weight — what DNA means for telehealth buyers
New genetics data from 23andMe and Stanford explains why some GLP-1 buyers fail to lose weight, highlighting genetic blocks and emotional eating patterns.
RxPros launches $89.97 flat-rate semaglutide — challenging telehealth price floors
RxPros launches flat-rate compounded semaglutide for $89.97 and tirzepatide for $119.97. See how this pricing reshapes the online GLP-1 market.
Novo partners with Novonesis on synbiotics — the plan to pair microbiome supplements with GLP-1s
Novo Nordisk and Novonesis target 2027 for clinical trial results testing synbiotic gut supplements alongside GLP-1 drugs to boost metabolic health.
FDA updates Orange Book semaglutide patents — what it changes for generic Ozempic timing
FDA updates the Orange Book registry as a key semaglutide patent approaches its March 2026 expiration. Learn what this means for generic Ozempic timing.
FDA targets bulk GLP-1 ingredients — what the proposed 503B ban changes for compounded buyers
The FDA proposes excluding semaglutide and tirzepatide from the 503B Bulks List, threatening the supply of low-cost compounded telehealth GLP-1s.
FDA warns against semaglutide salt forms — why base ingredients matter for compounded GLP-1 buyers
The FDA warns that semaglutide sodium and acetate are unauthorized salts with no legal compounding basis, raising safety risks for US GLP-1 buyers.
Survey reveals 15% of GLP-1 users are microdosing — how patients bypass standard doses online
An Evidation Health survey shows 15% of GLP-1 users are microdosing. Learn why patients are taking lower doses to cut side effects and costs.
Bariatric surgeries plunge 34% as GLP-1 use surges 140% — the cost shift for US buyers
New Wells Fargo and JAMA data show bariatric surgeries fell 34% as GLP-1 use surged 140%. What this metabolic shift means for US weight-loss buyers.
Employers turn to GLP-1 point solutions — how benefit managers are reshaping online weight loss access
As corporate GLP-1 coverage stabilizes, employers are deploying strict point-solution vendors to ration access, driving buyers to online telehealth.
Celon Pharma’s Reduzek matches Wegovy in trial — paving way for cheaper generic semaglutide
Celon Pharma’s Reduzek matches Wegovy and Ozempic in a new clinical trial, paving the way for affordable, FDA-approved generic semaglutide for US buyers.
Why am I not losing weight on Wegovy? — How to troubleshoot semaglutide non-response
Not losing weight on Wegovy or Ozempic? Learn why 10% to 17% of patients don't respond to semaglutide and how to troubleshoot your dose or swap drugs.
FDA approves second oral GLP-1 weight-loss pill — expanding needle-free choices for US buyers
The FDA has approved a second daily oral GLP-1 pill for chronic weight management, expanding needle-free clinical choices for US telehealth buyers.
FDA targets unapproved retatrutide compounding — closing next-gen peptide paths for online buyers
FDA targets unapproved compounders selling retatrutide and cagrilintide. Learn what warning letters mean for online buyers and GLP-1 safety.
Study reveals 48% of GLP-1 users turn to social media over doctors — the safety gap in online weight loss
A new peer-reviewed study shows 48% of GLP-1 users rely on social media over doctors for clinical advice. What this means for US weight-loss telehealth buyers.
UTMB launches tirzepatide anti-aging trial — opening longevity paths for GLP-1 buyers
Researchers at UTMB launch a clinical trial to test if Eli Lilly's tirzepatide (Zepbound) can slow biological aging by 10% to 15% in older US adults.
Novo launches OASIS-5 trial for lower oral Wegovy doses — what clinical microdosing means for US buyers
Novo Nordisk has launched the OASIS-5 trial to find the lowest effective dose for its oral Wegovy pill, a move that could cut side effects and costs.
Conagra designs food for the 'not-so-hungry' — what Big Food's GLP-1 pivot changes for US buyers
Big Food companies like Conagra are reformulating recipes and shrinking portion sizes to target GLP-1 users who experience drug-induced appetite loss.
Trial shows switching to oral GLP-1 maintains weight loss — providing a needle-free path for US buyers
A new clinical trial shows switching from injectable to oral GLP-1 therapy maintains weight loss, providing a needle-free maintenance option for US buyers.
Tirzepatide linked to higher hair loss than semaglutide — what alopecia data means for GLP-1 buyers
A new large-scale data analysis reveals tirzepatide (Zepbound) carries a higher risk of temporary hair loss than semaglutide (Wegovy). Read the pricing math.
Starbucks cuts employee GLP-1 coverage — driving retail workers to telehealth cash options
Starbucks ends employee GLP-1 weight-loss insurance coverage, forcing retail workers to choose between $1,300 retail costs and telehealth cash alternatives.
Researchers identify anti-inflammatory effects of GLP-1s — opening new off-label paths for pain and arthritis
Top metabolic researchers confirm GLP-1 drugs target chronic inflammation independently of weight loss, opening new off-label paths for arthritis and pain.
Major insurers restrict GLP-1 weight loss coverage — driving US buyers to telehealth cash options
Major commercial insurers will restrict or deny GLP-1 weight-loss coverage starting Jan 1, 2026, driving US buyers toward cash-pay telehealth options.
FDA limits bulk GLP-1 compounding — how the 503A vs 503B squeeze changes online weight-loss buying
The FDA limits bulk GLP-1 compounding by shutting down 503B outsourcing, pushing online buyers to smaller, patient-specific 503A pharmacies.
Nestlé launches $499 compounded tirzepatide — challenging telehealth startups with corporate scale
Nestlé enters the medical weight-loss market with a $499 compounded tirzepatide program, bringing corporate competition to telehealth GLP-1 startups.
FDA signals end of bulk GLP-1 compounding — what it changes for telehealth buyers
The FDA signals the end of bulk GLP-1 compounding. Learn how tightening 503A/503B rules impact low-cost compounded semaglutide and tirzepatide.
FDA approves oral Wegovy pill — opening a needle-free path for telehealth buyers
The FDA has approved Novo Nordisk’s daily oral Wegovy pill, giving US weight-loss telehealth buyers an official needle-free option. Here is the pricing math.
WADA monitors GLP-1 use in sports — shifting how US consumers view metabolic conditioning
As elite athletes like Serena Williams use tirzepatide, sports agencies debate whether GLP-1s are performance-enhancing. What this means for US buyers.
GLP-1 trials show success treating PCOS — opening new off-label paths for US women
Clinical trials show GLP-1 weight-loss drugs successfully treat PCOS, restoring ovulation and balancing hormones. What this means for US telehealth buyers.
Lawsuits target Novo Nordisk and Eli Lilly over eye strokes — what NAION risks mean for US GLP-1 buyers
A multi-district lawsuit consolidates over 130 cases alleging GLP-1 drugs like Wegovy cause permanent vision loss. What US buyers need to know.
FDA panel green-lights select peptides — signaling regulatory shift for custom compounders
An FDA panel green-lights select peptides for compounding and HHS moves 14 restricted peptides to Category 1, shifting the US custom compounding market.
Nestlé uses AI to target GLP-1 side effects — addressing muscle loss and 'Ozempic face'
Nestlé is leveraging AI and clinical data to develop targeted nutritional products that combat GLP-1 side effects like muscle loss and 'Ozempic face'.
FDA begins reviewing first generic tirzepatide applications — opening path to cheaper Zepbound alternatives
The FDA has started reviewing the first generic tirzepatide applications, marking the first major regulatory step toward cheaper Zepbound alternatives.
Dentist warns GLP-1s cause dry mouth — raising risk of rapid tooth decay for US buyers
Dentists warn that GLP-1 medications like Ozempic and Wegovy can cause severe dry mouth, lowering oral pH and accelerating tooth decay and gum disease.
FDA urges consumers to report unlawful online GLP-1 sales — how to spot and avoid counterfeit weight-loss drugs
The FDA is urging consumers to report illegal online drug sales amid a rise in counterfeit GLP-1s. Learn how to safely navigate telehealth options.
JAMA study reveals 10% of eating disorder patients misuse GLP-1s — forcing telehealth screening shift
A landmark JAMA Psychiatry study reveals that nearly one-third of individuals with eating disorders use GLP-1s, with over 10% misusing them to restrict food.
India launches $3.90 generic semaglutide — exposing the real cost of weight-loss drugs to US buyers
Indian generic drugmakers launch $3.90 semaglutide injections after Novo Nordisk's patent expires, signaling future price disruptions for US GLP-1 buyers.
Youth obesity surgery rates plummet to 4% — as GLP-1 therapies reshape pediatric care
A new JAMA Pediatrics study reveals youth obesity treatment is shifting rapidly from bariatric surgery to GLP-1 medications like Wegovy and Zepbound.
Medicare launches GLP-1 Bridge program — slashing weight-loss drug costs to $50 for seniors
The new Medicare GLP-1 Bridge program slashes the cost of weight-loss drugs to a flat $50 monthly copay for eligible US seniors. Learn if you qualify.
Australia reports 62 deaths linked to GLP-1 drugs — what safety data means for US buyers
Australia reports 62 deaths and 2,800 adverse events linked to GLP-1s. Doctors explain why association doesn't equal causation for US buyers.
Eli Lilly sues 14 generic rivals — delaying cheaper Zepbound and Mounjaro alternatives
Eli Lilly files 14 patent lawsuits against generic rivals in Delaware to block cheaper versions of Mounjaro and Zepbound. What this means for US buyers.
85% of eligible MS patients miss GLP-1 therapies — highlighting US healthcare access gaps
A new study shows 85% of eligible MS patients miss out on GLP-1s like Wegovy and Ozempic, exposing major care gaps for patients with complex conditions.
PBMs partner with TrumpRx to display insurance copays — exposing real GLP-1 costs
10 PBMs partner with the TrumpRx website to display commercial, Medicare, and Medicaid copays alongside direct-to-consumer cash prices for GLP-1 drugs.
Foundayo scripts climb as Wegovy pill hits 33% ceiling — reshaping the oral GLP-1 rivalry
Eli Lilly's Foundayo oral GLP-1 pill scripts surge to nearly 39,000, while Novo Nordisk's oral Wegovy hits a 33% franchise market share ceiling.
Harvard study reveals GLP-1s boost women's hiring rates by 27% — highlighting the career toll of weight bias
A new Harvard study reveals unemployed women taking GLP-1s are 27% more likely to get hired, highlighting the reality of workplace weight bias.
FDA warns 25 telehealth and compounding firms — revealing under-strength GLP-1 doses
The FDA issued warning letters to 25 telehealth and compounding firms over misleading GLP-1 marketing and distributed under-strength drug batches.
Medicare launches $50 copay cap for weight-loss GLP-1s — slashing senior costs
Medicare has expanded coverage to include certain GLP-1 weight-loss medications for a flat $50 monthly copay starting July 1, 2026. Learn if you qualify.
GLP-1 Users Cut Ice Cream Consumption by 10% — How Food Giants Are Pivoting to Wellness Treats
GLP-1 users have cut ice cream consumption by 10%, forcing brands like Ben & Jerry's, Blue Bunny, and Halo Top to pivot to high-protein, mini portions.
Employers cut GLP-1 coverage over soaring costs — driving US buyers to telehealth alternatives
With 31% of employers considering cutting GLP-1 benefits, patients face massive out-of-pocket costs, fueling a major shift toward telehealth.
Lawmakers press FDA over counterfeit GLP-1s — protecting telehealth buyers from dangerous imitations
Congress demands FDA action against counterfeit GLP-1 ingredients. Learn how to spot fake Ozempic and safely buy weight-loss drugs online.
CompareRx Daily
Today's GLP-1 news in your inbox
Five stories every morning on GLP-1 pricing, insurance coverage, shortages, and new provider deals — written by our newsroom and free to read.
Five stories a day. Free, no spam, unsubscribe in one click.
News is useful. Your match is actionable.
Answer a 90-second questionnaire and see the three providers that fit your budget, state and medication preference.
Get my top 3 matches